JasonLukasMDPhD

PubMed

• 15 citations
  Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressin...
  R. Connor Chick, G. Travis Clifton, Diane F. Hale, Timothy J. Vreeland, Phillip M. Kemp Bohan, Patrick M. McCarthy, Jennifer K. Litton, Gheath Alatrash, Rashmi Krishna...> ;Clinical Immunology. 2021 Jan 22
• 48 citations
  Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast ...
  G. Travis Clifton, Diane F. Hale, Timothy J. Vreeland, Jennifer K. Litton, Gheath Alatrash, Rashmi Krishna Murthy, Na Qiao, Anne V. Philips, Jason Lukas, Jarrod P. Hol...> ;Clinical Cancer Research. 2020 Jun 1
• 13 citations
  Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer p...
  G. Travis Clifton, Kaitlin M. Peace, Jarrod P. Holmes, Timothy J. Vreeland, Diane F. Hale, Garth S. Herbert, Jennifer K. Litton, Rashmi Krishna Murthy, Jason Jerome Lu...> ;Clinical Immunology. 2019 Apr 1
• The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.
  Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, Papafotiou...> ;Cell Death Differ.. 2013-11-01
• 122 citations
  The Major Reverse Transcriptase–Incompetent Splice Variant of the Human Telomerase Protein Inhibits Telomerase Activity but Protects from Apoptosis
  Imke Listerman, Jie Sun, Francesca S. Gazzaniga, Jason L. Lukas, Elizabeth H. Blackburn> ;Cancer Research. 2013 May 1
• Heterochromatin marks HP1γ, HP1α and H3K9me3, and DNA damage response activation in human testis development and germ cell tumours.
  Bartkova J, Moudry P, Hodny Z, Lukas J, Rajpert-De Meyts E, Bartek J> ;Int. J. Androl.. 2011-08-01
• Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.
  Bartkova J, Hamerlik P, Stockhausen M, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J> ;Oncogene. 2010-09-09
• The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
  Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, Aittomäki K, Hofstetter B, Lukas J, von Smitten K, Blomqvist C, Ristimäki A, Heikkilä P, Bartek ...> ;Oncogene. 2008-04-10
• DNA damage signalling guards against activated oncogenes and tumour progression.
  Bartek J, Bartkova J, Lukas J> ;Oncogene. 2007-12-10
• DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours.
  Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J> ;Oncogene. 2007-11-22
• DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy.
  Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J> ;Int. J. Androl.. 2007-08-01
• 98 citations
  IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
  Keith L. Knutson, Yushe Dang, Hailing Lu, Jason Lukas, Bond Almand, Ekram Gad, Ehizoje Azeke, Mary L. Disis> ;Journal of Immunology. 2006 Jul 1
• 10 citations
  Nucleic acid molecular biomarkers for diagnostic biodosimetry applications: use of the fluorogenic 5'-nuclease polymerase chain reaction assay.
  William F. Blakely, Alexandra C. Miller, Lei Luo, Jason Lukas, Zachary D. Hornby, Christine J. C. Hamel, Joseph T. Nelson, Nestor E. Escalada, Pataje G. S. Prasanna> ;Military Medicine. 2002 Feb 1
• Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours.
  Bartkova J, Falck J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J> ;Oncogene. 2001-09-13
• DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology.
  Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, Sehested M, Lukas J, Bartek J> ;Cancer Res.. 2001-07-01
• 122 citations
  Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
  Jason Lukas, Da-Qing Gao, Mariana Keshmeshian, Wenhsiang Wen, Denice D. Tsao-Wei, Shoshana M. Rosenberg, Michael F. Press> ;Cancer Research. 2001 Apr 1
• Rapid destruction of human Cdc25A in response to DNA damage.
  Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J, Lukas J> ;Science. 2000-05-26
• 47 citations
  p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian Carcinoma
  Annette Schmider, Conway Gee, Wolfgang Friedmann, Jason Lukas, Michael F. Press, Werner Lichtenegger, Angela Reles> ;Gynecologic Oncology. 2000 May 1
• Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.
  Thullberg M, Bartkova J, Khan S, Hansen K, Rönnstrand L, Lukas J, Strauss M, Bartek J> ;FEBS Lett.. 2000-03-24
• Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors.
  Thullberg M, Welcker M, Bartkova J, Kjerulff AA, Lukas J, Högberg J, Bartek J> ;Hybridoma. 2000-02-01
• 41 citations
  p53 Mutations and Expression in Breast Carcinoma in Situ
  Jason Lukas, Ning Niu, Michael F. Press> ;The American Journal of Pathology. 2000 Jan 1
• Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
  Lukas C, Jensen SK, Bartkova J, Lukas J, Bartek J> ;Hybridoma. 1999-06-01
• 32 citations
  MDR1 gene expression in primary and advanced breast cancer.
  Xiaowei Yang, Beatrice Uziely, Susan Groshen, Jason Lukas, Valerie Israel, Christy A. Russell, Gary L. Dunnington, Silvia C. Formenti, Franco M. Muggia, Michael F. Press> ;Laboratory Investigation; a Journal of Technical Methods and Pathology. 1999 Mar 1
• Perspective: defects in cell cycle control and cancer.
  Bartek J, Lukas J, Bartkova J> ;J. Pathol.. 1999-01-01
• p21WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells.
  Welcker M, Lukas J, Strauss M, Bartek J> ;Cancer Res.. 1998-11-15
• Join now to see all